Amicus Therapeutics Inc. (FOLD)
Factsheet
-
Market Capitalisation
$3,645 Mln
-
-
Price to Earnings Ratio
--
-
12 Month Earnings
$-204 Mln
Amicus Therapeutics Inc. (FOLD) Share Price
NASDAQ
$10.55
As on 27-Nov-2023 16:00 EST
$-0.04
•
-0.38%
As on 27-Nov-2023 16:00 EST
-
Prev Close
$10.59
-
Day's Open
$10.60
-
Today's High
$10.68
-
Today's Low
$10.39
-
Today's Volume
1,477,561
-
52 Week range
$9.70 - 14.10
Please wait...
Amicus Therapeutics Inc. (FOLD) Stock Performance
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Amicus Therapeutics (FOLD)
| -13.60 | -2.85 | -16.67 | -8.18 | -22.61 | -0.89 | 16.50 |
|
S&P BSE Sensex*
| 8.77 | 3.75 | 1.98 | 6.23 | 14.44 | 13.26 | 12.48 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.90 | -6.30 | 5.30 | 2.98 | 5.53 |
As on 27-Nov-2023
| *As on 28-Nov-2023 | #As on 26-Oct-2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|
|---|---|---|---|---|---|---|---|
|
Amicus Therapeutics (FOLD)
| 5.71 | -49.98 | 137.06 | 1.67 | -33.28 | 189.54 | -48.76 |
|
S&P Small-Cap 600
| -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 | 24.74 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 |
Valuation
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
Growth & Efficiency
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
Solvency
Is there a threat to this company's solvency in the future?
Financial Manipulation
Can creative accounting be detected through the financial numbers?
Amicus Therapeutics Inc. (FOLD) Peer Comparison
Please wait...
Valuation Chart of Amicus Therapeutics Inc. (FOLD)
Please wait...
Please wait...
Financials
Please wait...
Please wait...
Please wait...
Shareholding Pattern
Other details of Amicus Therapeutics Inc. (FOLD)
Exec. Chairman
Mr. John F. Crowley
CEO, Pres & Director
Mr. Bradley L. Campbell M.B.A.
Headquarters
Philadelphia, PAWebsite
https://amicusrx.comFAQs for Amicus Therapeutics Inc. (FOLD)
What is the total asset value of Amicus Therapeutics Inc. (FOLD)?
The total asset value of Amicus Therapeutics Inc. (FOLD) stood at $ 839 Mln as on 31-Mar-23
What is the current share price of Amicus Therapeutics Inc. (FOLD)?
The share price of Amicus Therapeutics Inc. (FOLD) is $10.55 (NASDAQ) as of 27-Nov-2023 16:00 EST. Amicus Therapeutics Inc. (FOLD) has given a return of -22.61% in the last 3 years.
What is the market cap of Amicus Therapeutics Inc. (FOLD)?
Amicus Therapeutics Inc. (FOLD) has a market capitalisation of $ 3,645 Mln as on 09-Jun-2023. As per Value Research classification, it is a Small Cap company.
What is the current PB ratio of Amicus Therapeutics Inc. (FOLD)?
The P/B ratio of Amicus Therapeutics Inc. (FOLD) is 24.77 times as on 09-Jun-2023, a 8.75% premium to its peers’ median range of 2.54 times.
What is the current P/E ratio of Amicus Therapeutics Inc. (FOLD)?
Since, TTM earnings of Amicus Therapeutics Inc. (FOLD) is negative, P/E ratio is not available.
How can you buy shares of Amicus Therapeutics Inc. (FOLD)?
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Amicus Therapeutics Inc. (FOLD) and enter the required number of quantities and click on buy to purchase the shares of Amicus Therapeutics Inc. (FOLD).
What is the main business of Amicus Therapeutics Inc. (FOLD)?
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Who are the promoters/managers of Amicus Therapeutics Inc. (FOLD)?
The CEO & director of Mr. John F. Crowley. is Amicus Therapeutics Inc. (FOLD), and CFO & Sr. VP is Mr. Bradley L. Campbell M.B.A..
What is the total promoter pledging in Amicus Therapeutics Inc. (FOLD)?
The promoters of Amicus Therapeutics Inc. (FOLD) have pledged 0% of the total equity as on Mar-23.
Who are the competitors of Amicus Therapeutics Inc. (FOLD)?
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
524
|
|
|
377
|
|
|
330
|
|
|
217
|
What are the key ratios of Amicus Therapeutics Inc. (FOLD)?
| Amicus Therapeutics Inc. (FOLD) | Ratios |
|---|---|
|
Return on equity(%)
|
-173.72
|
|
Return on capital employed(%)
|
--
|
|
Debt-to-equity ratio
|
3.83
|
|
Dividend yield(%)
|
0
|
Is the Amicus Therapeutics Inc. (FOLD) profitable?
No, TTM profit after tax of Amicus Therapeutics Inc. (FOLD) was $-204 Mln.
Edit
Please wait...
Please wait...
Key Facts
-
Market cap
$3,645.42 Mln
-
Revenue (TTM)
$336.79 Mln
-
Earnings (TTM)
$-204.24 Mln
-
Cash
$267.11 Mln
-
Total Debt
$452.01 Mln
- Insider's Holding 0.86%
-
Liquidity
High
-
52 Week range
$9.70 - 14.10
-
Shares outstanding
284,576,000
-
10 Years Aggregate:
CFO: $-1,716.35 Mln
EBITDA: $-2,152.51 Mln
Net Profit: $-2,213.98 Mln
About The Company
- IPO Date 31-May-2007
- Exec. Chairman Mr. John F. Crowley
- CEO, Pres & Director Mr. Bradley L. Campbell M.B.A.
-
Listing
NASDAQ: FOLD
- Country United States
-
Headquarters
Philadelphia, PA
-
Website
https://amicusrx.com
-
Business
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults... with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania. Read more
